Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
Farnesyltransferase inhibitors (FTIs) block the growth of tumor cells in vitro and in vivo with minimal toxicity toward normal cells. In general, inhibition of protein farnesylation results in G0/G1 cell cycle block, G2/M cell cycle arrest, or has no effect on cell cycle progression. One aspect of FTI biology that ... is poorly understood is the ability of these drugs to induce cancer cell growth arrest at the G2/M phase of cell cycle. In the present study, we investigated the effects of the farnesyltransferase inhibitor FTI-277 on two human liver cancer cell lines, HepG2 and Huh7. Treatment of these cells with FTI-277 inhibited Ras farnesylation in a dose-dependent manner. Both HepG2 and Huh7 cell growth was inhibited by FTI-277 and cells accumulated at the G2/M phase of the cell cycle. In HepG2 and Huh7 cells, FTI-277 induced an up-regulation of the cyclin-dependent kinase inhibitor p27(Kip1) without affecting the cellular levels of p53 and p21(Waf1). This event correlated with reduced activity of the cyclin-dependent kinase 2 and cyclin-dependent kinase 1. Moreover, increased expression of Bcl-2 protein was observed in HepG2 and Huh7 cells treated with FTI-277, and this was coincidental with reduced association between Raf-1 and Bcl-2. Finally, transient transfection of a dominant-negative Ras allele induced Bcl-2 expression and reduced Bcl-2/Raf-1 association demonstrating a requirement for Ras. Taken together, these findings show that increased expression of p27(Kip1) and Bcl-2 is concomitant with altered association between Ras, Raf-1 and Bcl-2 and suggest that this is responsible for the growth-inhibitory properties of FTI-277.
Mesh Terms:
Alkyl and Aryl Transferases, CDC2-CDC28 Kinases, CDC28 Protein Kinase, S cerevisiae, Cell Cycle Proteins, Cell Division, Cyclin-Dependent Kinase 2, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase Inhibitor p27, Cyclin-Dependent Kinases, Cyclins, Enzyme Inhibitors, Farnesyltranstransferase, G2 Phase, Gene Expression, Humans, Methionine, Mitosis, Protein-Serine-Threonine Kinases, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-raf, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Tumor Suppressor Proteins, rap1 GTP-Binding Proteins, ras Proteins
Alkyl and Aryl Transferases, CDC2-CDC28 Kinases, CDC28 Protein Kinase, S cerevisiae, Cell Cycle Proteins, Cell Division, Cyclin-Dependent Kinase 2, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase Inhibitor p27, Cyclin-Dependent Kinases, Cyclins, Enzyme Inhibitors, Farnesyltranstransferase, G2 Phase, Gene Expression, Humans, Methionine, Mitosis, Protein-Serine-Threonine Kinases, Proto-Oncogene Proteins c-bcl-2, Proto-Oncogene Proteins c-raf, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Tumor Suppressor Proteins, rap1 GTP-Binding Proteins, ras Proteins
Mol. Pharmacol.
Date: Jan. 01, 2003
PubMed ID: 12488548
View in: Pubmed Google Scholar
Download Curated Data For This Publication
154257
Switch View:
- Interactions 1